2. Search Result
Search Result
Isoforms Recommended: EZH1
Results for "

EZH1

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Peptides

2

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13803
    Tazemetostat
    Maximum Cited Publications
    89 Publications Verification

    EPZ-6438; E-7438

    		 Histone Methyltransferase Apoptosis Cancer
    Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells [1].
    Tazemetostat
  • HY-109108
    Valemetostat
    5 Publications Verification

    DS-3201

    		 Histone Methyltransferase Cancer
    Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma [1] .
    Valemetostat
  • HY-145602
    Tulmimetostat

    CPI-0209

    		 Histone Methyltransferase Cancer
    Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor that targets and inhibits the EZH2 enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies [1] .
    Tulmimetostat
  • HY-109108A
    Valemetostat tosylate
    5 Publications Verification

    DS-3201 tosylate

    		 Histone Methyltransferase Cancer
    Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma [1] .
    Valemetostat tosylate
  • HY-15555
    EPZ005687
    5 Publications Verification

    		 Histone Methyltransferase Cancer
    EPZ005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.
    EPZ005687
  • HY-13803R
    Tazemetostat (Standard)

    EPZ-6438 (Standard); E-7438 (Standard)

    		 Reference Standards Histone Methyltransferase Apoptosis Cancer
    Tazemetostat (Standard) is the analytical standard of Tazemetostat. This product is intended for research and analytical applications. Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells [1].
    Tazemetostat (Standard)
  • HY-148458
    EZH2-IN-14

    		Histone Methyltransferase Cancer
    EZH2-IN-14 is a selective EZH2 (Histone Methyltransferase) inhibitor with an IC50 of 12 nM. EZH2-IN-14 inhibits the methyltransferase activity of EZH2/PRC2 (that is, reducing H3K27me3). EZH2-IN-14 shows >200-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1 [1].
    EZH2-IN-14
  • HY-144881
    (S)-HH2853

    		Histone Methyltransferase Inflammation/Immunology Cancer
    (S)-HH2853 (compound 200), a PYRIDINO five membered aromatic ring compound, is a potent EZH1/2 dual inhibitor with an IC50 of <100 nM for EZH2_Y641F. (S)-HH2853 has the potential to be used in the research of anti-tumor or autoimmune diseases [1].
    (S)-HH2853
  • HY-RS04617
    Ezh1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ezh1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ezh1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ezh1 Mouse Pre-designed siRNA Set A
    Ezh1 Mouse Pre-designed siRNA Set A
  • HY-RS04616
    EZH1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    EZH1 Human Pre-designed siRNA Set A contains three designed siRNAs for EZH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    EZH1 Human Pre-designed siRNA Set A
    EZH1 Human Pre-designed siRNA Set A
  • HY-RS04618
    Ezh1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ezh1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ezh1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ezh1 Rat Pre-designed siRNA Set A
    Ezh1 Rat Pre-designed siRNA Set A
  • HY-178446
    METTL3-IN-11

    		METTL3 c-Myc Bcl-2 Family Cancer
    METTL3-IN-11 is an excellent, selective METTL3 inhibitor (IC50 = 45.31 nM). METTL3-IN-11 exhibits high selectivity towards METTL3 compared to DNMT1, EZH1, MLL1, and PRMT1. METTL3-IN-11 reduces the m6A level of total RNA in MOLM-13 and SKOV3 cells, induces cell apoptosis, and inhibits cell migration. METTL3-IN-11 can reduce the expression of m6A downstream target genes (c-MYC and BCL2). METTL3-IN-11 can be used for the study of ovarian cancer and acute myeloid leukemia [1].
    METTL3-IN-11
  • HY-P2266
    SAH-EZH2

    		Histone Methyltransferase Cancer
    SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 [1].
    SAH-EZH2
  • HY-122595
    EZH2-IN-1

    		Histone Methyltransferase Cancer
    EZH2-IN-1 (compound 3) is a selective and SAM-competitive EZH2 and EZH1 inhibitor with an IC50s of 32 nM, 197 nM and 213 nM for EZH2wt, EZH2 Y641N mutant and EZH1, respectively. EZH2-IN-1 reduces bulk H3K27me3 and H3K27me2 levels. EZH2-IN-1 has the potential for diffuse large B cell lymphoma research [1].
    EZH2-IN-1
  • HY-117947
    (R)-OR-S1

    		Histone Methyltransferase Cancer
    (R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.
    (R)-OR-S1
  • HY-181327
    PROTAC EZH2 Degrader-26

    		PROTACs Histone Methyltransferase Others
    PROTAC EZH2 Degrader-26 (compound 11) is an EZH2 degrader developed based on PROTAC technology. PROTAC EZH2 Degrader-26 has an IC50 of 5.80 nM against EZH2. PROTAC EZH2 Degrader-26 exhibits micromolar-level enzyme inhibitory activity against EZH1, with an EZH1 IC50 of 0.06 μM [1].
    PROTAC EZH2 Degrader-26
  • HY-181307
    PROTAC EZH2 Degrader-12

    		PROTACs Histone Methyltransferase Cancer
    PROTAC EZH2 Degrader-12 (compound 3) is a CRBN-recruiting PROTAC-based EZH2 degrader with an EZH2 IC50 of 3.90 nM and EZH1 IC50 of 5.24 μM [1].
    PROTAC EZH2 Degrader-12
  • HY-181334
    PROTAC EZH2 Degrader-39

    		PROTACs Histone Methyltransferase Cancer
    PROTAC EZH2 Degrader-39 (compound 18) is a PROTAC protein degrader targeting EZH2 with a target IC50 of 61.00 nM. PROTAC EZH2 Degrader-39 functionally inhibits EZH2 methyltransferase activity [1].
    PROTAC EZH2 Degrader-39
  • HY-181305
    PROTAC EZH2 Degrader-10

    		PROTACs Histone Methyltransferase Cancer
    PROTAC EZH2 Degrader-10 (compound 1) is a PROTAC protein degrader targeting EZH2. PROTAC EZH2 Degrader-10 can be used for the research of cancer [1].
    PROTAC EZH2 Degrader-10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: